Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, has announced the 36-month results from its Phase 1/2a clinical study of RG6501 (OpRegen) for patients with geographic atrophy secondary to age-related macular degeneration. These results were presented at the Clinical Trials at the Summit 2025 by Dr. Christopher D. Riemann. The study demonstrated mean vision gains of +9 letters in patients who received extensive coverage of OpRegen cell therapy at the lesion site, with evidence of retinal structural improvement persisting for three years. This suggests anatomical and functional improvements following a single administration of the therapy. Additionally, the Phase 2a "GAlette study," which is evaluating the subretinal delivery of OpRegen cell therapy, is currently enrolling participants.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。